Kilic, L. Et Al. 2016. RITUXIMAB SEEMS OUTSTANDING BIOLOGICAL OPTION IN LATE ONSET RHEUMATOID ARTHRITIS: HUR-BIO REAL LIFE RESULTS. Annual European Congress of Rheumatology (EULAR) , (London, Canada), 1022-1023.

Kilic, L., Erden, A., Sari, A., Armagan, B., Karadag, O., Akdogan, A., ... Bilgen, S. A.(2016). RITUXIMAB SEEMS OUTSTANDING BIOLOGICAL OPTION IN LATE ONSET RHEUMATOID ARTHRITIS: HUR-BIO REAL LIFE RESULTS . Annual European Congress of Rheumatology (EULAR) (pp.1022-1023). London, Canada

Kilic, L. Et Al. "RITUXIMAB SEEMS OUTSTANDING BIOLOGICAL OPTION IN LATE ONSET RHEUMATOID ARTHRITIS: HUR-BIO REAL LIFE RESULTS," Annual European Congress of Rheumatology (EULAR), London, Canada, 2016

Kilic, L. Et Al. "RITUXIMAB SEEMS OUTSTANDING BIOLOGICAL OPTION IN LATE ONSET RHEUMATOID ARTHRITIS: HUR-BIO REAL LIFE RESULTS." Annual European Congress of Rheumatology (EULAR) , London, Canada, pp.1022-1023, 2016

Kilic, L. Et Al. (2016) . "RITUXIMAB SEEMS OUTSTANDING BIOLOGICAL OPTION IN LATE ONSET RHEUMATOID ARTHRITIS: HUR-BIO REAL LIFE RESULTS." Annual European Congress of Rheumatology (EULAR) , London, Canada, pp.1022-1023.

@conferencepaper{conferencepaper, author={L. Kilic Et Al. }, title={RITUXIMAB SEEMS OUTSTANDING BIOLOGICAL OPTION IN LATE ONSET RHEUMATOID ARTHRITIS: HUR-BIO REAL LIFE RESULTS}, congress name={Annual European Congress of Rheumatology (EULAR)}, city={London}, country={Canada}, year={2016}, pages={1022-1023} }